Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 12th International Symposium on Hodgkin Lymphoma (ISHL12) was held in Cologne, Germany, and virtually, on October 22-24 2022, and provided an overview of the most exciting advances in the diagnosis, treatment, biology, and clinical research of Hodgkin lymphoma (HL). This year, the meeting focused on patients with early-stage disease, as well as elderly and frail patients.
View all videos

ISHL12 2022

The 12th International Symposium on Hodgkin Lymphoma
22–24 October 2022 | Cologne, Germany / Online
VJHemOnc avatar

VJHemOnc

@VJHemOnc ·
2 Nov 2117250429020987422

📖 Have you had a chance to read our newest feature article, focusing on BTK inhibitors in CLL and the move beyond covalent inhibition with the emergence of non-covalent agents and BTK degraders?

Click here to check it out:
👉 https://ow.ly/NmxG5101itW

#CLLsm #Leusm #Leukemia

Image for the Tweet beginning: 📖 Have you had a Twitter feed image.
Reply on Twitter 2117250429020987422 Retweet on Twitter 2117250429020987422 4 Like on Twitter 2117250429020987422 3 View Tweet 2117250429020987422

ISHL12 2022

The 12th International Symposium on Hodgkin Lymphoma
22–24 October 2022 | Cologne, Germany / Online
The 12th International Symposium on Hodgkin Lymphoma (ISHL12) was held in Cologne, Germany, and virtually, on October 22-24 2022, and provided an overview of the most exciting advances in the diagnosis, treatment, biology, and clinical research of Hodgkin lymphoma (HL). This year, the meeting focused on patients with early-stage disease, as well as elderly and frail patients.
View all videos
VJHemOnc avatar

VJHemOnc

@VJHemOnc ·
2 Nov 2117250429020987422

📖 Have you had a chance to read our newest feature article, focusing on BTK inhibitors in CLL and the move beyond covalent inhibition with the emergence of non-covalent agents and BTK degraders?

Click here to check it out:
👉 https://ow.ly/NmxG5101itW

#CLLsm #Leusm #Leukemia

Image for the Tweet beginning: 📖 Have you had a Twitter feed image.
Reply on Twitter 2117250429020987422 Retweet on Twitter 2117250429020987422 4 Like on Twitter 2117250429020987422 3 View Tweet 2117250429020987422

Latest videos

View all
0:51
The value of CAR-T cell therapy in R/R DLBCL
Peter Borchmann • 25 Oct 2022
2:32
The growing role of anti-PD1 inhibitors in the frontline treatment of HL
Paul Jan Bröckelmann • 17 Oct 2022
3:54
The use of TARC as a diagnostic biomarker in Hodgkin lymphoma
Arjan Diepstra • 26 Oct 2022
1:19
Using PET-adapted study designs to de-escalate treatment intensity in HL
Peter Borchmann • 25 Oct 2022

Immuno-Oncology

View all
0:51
The value of CAR-T cell therapy in R/R DLBCL
Peter Borchmann • 25 Oct 2022
2:32
The growing role of anti-PD1 inhibitors in the frontline treatment of HL
Paul Jan Bröckelmann • 17 Oct 2022
2:29
Findings from the HD21 trial: safety profile of the BrECADD regimen in HL
Peter Borchmann • 25 Oct 2022
2:11
The challenges with treating high-risk patients with HL: a Brazilian perspective
Irene Biasoli • 26 Oct 2022

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals